Back to News
Market Impact: 0.15
Akiram Therapeutics: First clinical results from AKIR001 to be presented at EANM 2026
Source: PR Newswire
Healthcare & Biotech
Akiram Therapeutics will present the first clinical data from its ongoing Phase I trial of lead candidate 177Lu-AKIR001 at the EANM 2026 Congress in Vienna, October 17–21. The announcement provides no trial results or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Document Search Enhancements, AI Enhancements, AI Actions, & Chat Export
- AI Vendor Landscape for Institutional Investment Teams